One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Finally, Canaccord Genuity reiterated a "buy" rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Tuesday, January 31st. In a separate announcement today, Seres reported fourth quarter and full year 2016 financial results and provided an update on multiple ongoing microbiome clinical programs.
On Jan. 31, the Cambridge, Mass. -based company, which raised $134 million in a 2015 initial public offering, had said that findings from its analysis of SER-109's phase 2 study failure suggested that misdiagnosis of some patients, and possible suboptimal dosing in others, contributed to the poor outcome.
The share price of the company (NASDAQ:MCRB) was down -5.27%, with a high of 12.85 during the day and the volume of Seres Health, Inc. shares traded was 863364. The higher price target estimate is at $18 while the lower price estimates are fixed at $12. Analysts believe that we could see stock price minimum in the $8 range (lowest target price), allowing for another -33.55% drop from its current position. Cantor Fitzgerald initiated coverage on shares of Seres Therapeutics in a research note on Friday, December 16th. Seres Therapeutics has a 1-year low of $8.05 and a 1-year high of $35.98. For the stock, price target value has been calculated at $14.71 based on calls of 7 experts.
ACI Worldwide, Inc. (NASDAQ:ACIW) traded 1.13 Million shares and its share price advanced 0.62% to close at $22.78. Additionally, MCRB had a day price range of $12 to $12.85. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.89, while the High earnings estimate is $-0.34.Comparatively, EPS for the same quarter previous year was $0. Investors might also notice that three month ago the Buy recommendations (6) outnumbered Sell recommendations (0). The firm's market cap is $485.87 million. The business earned $3 million during the quarter, compared to the consensus estimate of $3 million. But with the equity now in the red on a year-to-date basis, a round of downbeat brokerage attention could spell even more trouble. On average, equities research analysts expect that Seres Therapeutics will post ($2.40) EPS for the current year. Artal Group S.A. raised its stake in Seres Therapeutics by 40.0% in the fourth quarter. Renaissance Technologies LLC raised its stake in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the company's stock worth $3,963,000 after buying an additional 103,800 shares during the last quarter. ARK Investment Management LLC bought a new stake in shares of Seres Therapeutics during the fourth quarter worth about $4,871,000.
Seres Therapeutics, Inc.is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are created to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.